On Saturday, December 4, 2021, starting at 10:00 p.m. EST we will be launching the New FAST Graphs. This may cause temporary interruptions. We are sorry for any inconvenience this may cause.

Pfizer

Building A Dividend Growth Portfolio from Scratch in Today’s Expensive Market

2021-03-17

Research Articles

Introduction Building A Dividend Growth Portfolio Before we talk about a dividend growth portfolio, the stock market as measured by the S&P 500 is at an all-time high. However, that is not what concerns me. What I am worried about is the extremely high relative valuation of the market. To be clear, the market can […]

Is the New Pfizer an Attractive Investment?

2020-02-25

Research Articles

Introduction Pharmaceutical giant Pfizer (PFE) is a company in transition that will soon be smaller but hopefully more profitable.  Since many of their established drugs are coming off patent, the company is divesting its older drug platform under the Upjohn brand and selling it to Mylan a leading generic pharmaceutical company.  Pfizer believes that this […]

Pfizer Inc. Invest For Attractive Valuation and The 4% Dividend Yield

2017-02-22

Research Articles

Investment Thesis Pfizer Inc (PFE) is one of the world’s largest pharmaceutical firms with sales exceeding $50 billion.  The company is currently attractively valued at a blended P/E ratio of 13.3, offering a current dividend yield of 4%.  Pfizer is awarded an S&P credit rating of AA and possesses a modest debt to capital ratio […]

Disclaimers: F.A.S.T. Graphs, Inc. is not a broker-dealer or a registered investment adviser. Under no circumstances does any information on Fastgraphs.com constitute a recommendation to buy or sell a security, nor does it give investment advice. This is to include any publications or articles on Fastgraphs.com. Fastgraphs.com is a research tool to be used by its subscribers in conjunction with the subscribers’ additional research and due diligence. The information on this site is in no way guaranteed for completeness or accuracy.